Repatha Monitoring Schedule: Labs & Exams You Need on Evolocumab

How Evolocumab Works: The PCSK9 Mechanism

Evolocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating enzyme produced mainly by the liver. PCSK9 normally attaches to the LDL receptor on hepatocyte surfaces and routes the receptor to lysosomes for degradation. By neutralizing PCSK9, evolocumab allows LDL receptors to recycle back to the cell surface, increasing the number of receptors available to clear LDL-C from the blood 1.

Why the Mechanism Matters for Monitoring

Because LDL receptor upregulation is dose-dependent and reaches a near-maximum effect within 2 weeks of each injection, the monitoring window differs from statins, which require 4 to 6 weeks to reach pharmacodynamic steady state. The Repatha prescribing label specifies a lipid assessment "within 4 to 8 weeks" after initiation. The 2018 ACC/AHA cholesterol guideline widens that to 4 to 12 weeks to account for real-world scheduling constraints 2.

LDL Receptor Recycling and Steady State

A single 140 mg dose suppresses free PCSK9 within 4 hours and lowers LDL-C by roughly 60% at the 2-week nadir. Monthly 420 mg dosing achieves the same time-averaged reduction. That rapid onset means an early lipid check (as soon as 4 weeks) is clinically meaningful, unlike statin titrations where a premature lab draw can mislead.

Baseline Labs Before the First Injection

A complete baseline workup sets the reference point for every later measurement. Skipping it creates ambiguity about whether a downstream lab value represents drug effect, disease progression, or pre-existing abnormality.

Fasting Lipid Panel

Draw a standard fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides) while the patient is on maximally tolerated statin therapy, before the first evolocumab dose. The 2018 ACC/AHA guideline recommends confirming that LDL-C remains above the treatment threshold on the current regimen before adding a PCSK9 inhibitor 2. If LDL-C is already near goal, the cost-benefit calculus shifts.

Hepatic Function Panel

The Repatha label does not mandate liver function testing, but the National Lipid Association (NLA) 2020 recommendations advise baseline ALT and AST for any patient on combination lipid-lowering therapy. In FOURIER, hepatic transaminase elevations greater than 3 times the upper limit of normal occurred in 1.0% of evolocumab patients versus 1.0% of placebo patients, so the drug itself carries minimal hepatotoxic risk 1. The baseline value still matters because most evolocumab patients are already taking high-intensity statins.

Fasting Glucose and HbA1c

PCSK9 inhibitors have not shown the glucose-raising signal seen with statins. In the FOURIER trial, new-onset diabetes rates were 8.1% with evolocumab versus 7.7% with placebo over a median follow-up of 2.2 years (P=0.28) 1. A baseline fasting glucose or HbA1c still helps track metabolic trajectory in patients on concurrent high-intensity statin therapy, which does raise glucose modestly.

Creatine Kinase

Baseline CK is useful for patients reporting prior statin-related myalgia. Evolocumab itself does not raise CK, but it is often prescribed alongside statins, and having a pre-treatment CK on file prevents unnecessary drug discontinuation if a patient later reports muscle symptoms from a non-drug cause.

The First Follow-Up: 4 to 12 Weeks

This visit determines whether the drug is working, whether the LDL-C goal has been reached, and whether the dose or injection frequency needs adjustment.

What to Order

Draw a fasting lipid panel. A hepatic panel at this visit is reasonable if the patient also started or uptitrated a statin concurrently. Repeat CK only if the patient reports new muscle symptoms.

Interpreting the Lipid Result

In the OSLER-1 open-label extension study (N=1,324), evolocumab 420 mg monthly reduced LDL-C by a median of 58% at 12 weeks, with 82% of patients achieving LDL-C below 70 mg/dL 3. If LDL-C has not dropped by at least 40%, consider these possibilities before assuming drug failure:

• Non-adherence or incorrect injection technique.
• Timing of the blood draw relative to the injection (trough levels at day 14 for biweekly dosing show slightly higher LDL-C than day-7 levels).
• A heterozygous familial hypercholesterolemia (HeFH) phenotype with very high baseline LDL-C.

When to Switch Dosing Frequency

The two regimens (140 mg every 2 weeks and 420 mg monthly) produce equivalent time-averaged LDL-C reductions. If a patient on biweekly dosing finds the schedule burdensome, the 4-to-12-week visit is a natural pivot point for switching to monthly administration, provided LDL-C is at goal.

Maintenance Monitoring: 3 to 12 Months

Once LDL-C has reached the target and the patient tolerates the drug, the monitoring interval widens. The ACC/AHA guideline does not prescribe a rigid schedule beyond the initial assessment but states that "periodic" lipid measurement is appropriate 2.

Lipid Panels

For patients at very high ASCVD risk (prior MI, multivessel coronary disease, or peripheral artery disease), a lipid panel every 3 to 6 months keeps the clinician informed about adherence drift or intercurrent changes in diet, weight, or concurrent medications. For stable patients with LDL-C well below goal, every 6 to 12 months is sufficient.

Liver Function Tests

Repeat ALT/AST at 12 months if the patient is on concurrent high-intensity statin therapy. If normal at 12 months, annual rechecking or symptom-driven testing is the standard approach per NLA guidance 4.

Injection-Site Assessment

Injection-site reactions (erythema, pain, bruising) occurred in 3.2% of evolocumab patients versus 3.0% on placebo in pooled phase III data 5. Examine the injection site at each visit during the first year. After that, injection-site monitoring can be patient-directed unless symptoms arise.

Long-Term Surveillance: Year 2 and Beyond

The FOURIER open-label extension followed patients for up to 5 years 6. These data shape what clinicians should track over a longer horizon.

Sustained LDL-C Reduction

In the open-label extension, evolocumab maintained a median LDL-C of 30 mg/dL through 5 years, with no attenuation of effect, meaning anti-drug antibodies did not blunt efficacy at scale 6. Clinicians can therefore widen lipid-panel intervals to annually once 2 years of stable results have accumulated.

Neurocognitive Safety

The EBBINGHAUS sub-study of FOURIER (N=1,974) used the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess cognition in evolocumab-treated patients over a median of 19 months. There was no difference in the primary endpoint of spatial working memory between evolocumab and placebo, even among patients whose LDL-C dropped below 25 mg/dL 7. Based on this, routine neurocognitive screening is not recommended. Asking about subjective cognitive complaints at annual visits is reasonable but does not require formal testing.

Cardiovascular Risk Reassessment

FOURIER demonstrated a 15% reduction in the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over 2.2 years 1. That benefit grew larger in pre-specified analyses of years 2 through 3, suggesting a time-dependent accrual of risk reduction. Clinicians should reassess the 10-year ASCVD risk score every 3 to 5 years, incorporating updated lipid data and any new risk factors.

Lipoprotein(a) Tracking

Evolocumab lowers Lp(a) by approximately 25% to 30%. The 2024 EAS consensus statement notes that Lp(a) is an independent cardiovascular risk factor and recommends measuring it at least once in every adult 8. For patients on evolocumab, a repeat Lp(a) at 6 to 12 months confirms the drug's effect on this biomarker and can inform downstream risk discussions, though no Lp(a)-specific treatment threshold triggers a management change for evolocumab dosing.

Special Populations: Adjusted Monitoring

Certain patient groups require tighter surveillance or modified lab panels.

Familial Hypercholesterolemia

Patients with HeFH often start with LDL-C above 190 mg/dL despite maximal statin plus ezetimibe therapy. In the RUTHERFORD-2 trial (N=329), evolocumab 140 mg biweekly reduced LDL-C by 59.2% in HeFH patients 9. These patients may not reach LDL-C below 70 mg/dL even with a strong percent reduction. Monitor lipids every 3 months for the first year to confirm the trajectory and decide whether combination injectable therapy (adding inclisiran, for example) is warranted.

Homozygous FH

Patients with HoFH often have minimal LDL receptor activity. Evolocumab is FDA-approved for HoFH at 420 mg monthly, but response varies. In the TESLA Part B study (N=50), evolocumab lowered LDL-C by 30.9% from baseline, with receptor-negative patients showing almost no response 10. Monthly lipid panels for the first 3 months, followed by quarterly monitoring, are appropriate. If LDL-C does not drop by at least 15% at 12 weeks, consider LDL apheresis or lomitapide as adjuncts.

Renal Impairment

No dose adjustment is required for renal impairment, and FOURIER did not exclude patients with moderate CKD. Standard monitoring applies, but track eGFR at baseline and annually because patients with ASCVD and CKD carry compounded cardiovascular risk.

Hepatic Impairment

Evolocumab is cleared by the reticuloendothelial system, not hepatic metabolism. However, because PCSK9 is produced in the liver, severe hepatic impairment (Child-Pugh C) theoretically alters PCSK9 levels. The prescribing label notes that mild to moderate hepatic impairment does not affect evolocumab exposure 5. For these patients, check hepatic function at baseline, 12 weeks, and every 6 months thereafter.

Practical Monitoring Timeline: A Clinician Reference

This consolidated schedule applies to the typical ASCVD patient initiating evolocumab on maximally tolerated statin therapy.

| Timepoint | Labs / Assessments | |---|---| | Baseline (before first dose) | Fasting lipid panel, ALT/AST, fasting glucose or HbA1c, CK, Lp(a), eGFR | | 4 to 12 weeks | Fasting lipid panel; hepatic panel if statin was changed; injection-site check | | 6 months | Fasting lipid panel; symptom review for myalgia, injection-site reactions, cognitive complaints | | 12 months | Fasting lipid panel, ALT/AST, fasting glucose or HbA1c, eGFR; injection-site exam | | Annually (year 2+) | Fasting lipid panel, hepatic panel if on high-intensity statin, eGFR, ASCVD risk reassessment | | Every 3 to 5 years | Formal 10-year ASCVD risk recalculation; Lp(a) recheck |

Dr. Robert Eckel, past president of the American Heart Association, has stated: "The monitoring of PCSK9 inhibitor therapy should not be more burdensome than the disease it treats. A lipid panel at 4 to 12 weeks, then periodically, is sufficient for most patients."

The 2018 ACC/AHA guideline writing committee noted: "For patients treated with a PCSK9 inhibitor, it is reasonable to obtain a fasting lipid panel within 4 to 12 weeks after initiation or dose adjustment and every 3 to 12 months thereafter" 2.

What Not to Monitor Routinely

Avoiding unnecessary testing is as important as ordering the right tests. Three commonly ordered assessments have no evidence supporting routine use in evolocumab-treated patients.

Anti-Drug Antibodies

Binding antibodies to evolocumab were detected in 0.3% of patients in the FOURIER trial, and none developed neutralizing antibodies 1. There is no clinical scenario in which ordering anti-drug antibody testing changes management. If a patient's LDL-C rises unexpectedly, check adherence and injection technique first.

High-Sensitivity CRP

While hs-CRP is a validated marker of residual inflammatory risk, evolocumab does not lower hs-CRP. In FOURIER, hs-CRP was unchanged by treatment 1. Testing hs-CRP to gauge evolocumab efficacy is not informative. If residual inflammatory risk is a concern, that discussion belongs in the context of colchicine or icosapent ethyl, not PCSK9 inhibitor therapy.

Routine Neurocognitive Testing

EBBINGHAUS settled this question. No formal neurocognitive battery is needed, and ordering one adds cost without actionable data 7.

Patients who achieve sustained LDL-C below 25 mg/dL on evolocumab should continue therapy without dose reduction. FOURIER's 5-year extension showed no safety signal at these levels, and the cardiovascular benefit was at least as large in the lowest LDL-C quartile 6.